Loss of Chromosome Y and Risk of Abdominal Aortic Aneurysm - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Y-Chromosome Loss and Its Association With Abdominal Aortic Aneurysm Risk

  • By

  • Taylor Nordan

  • Tiffany R. Bellomo

  • Md Mesba Uddin

  • Liying Xue

  • So Mi Jemma Cho

  • Kaavya Paruchuri

  • Marie Billaud

  • Peter Libby

  • Pradeep Natarajan

  • Tetsushi Nakao

  • November 1, 2026

Share

Clinical Scorecard: Y-Chromosome Loss and Its Association With Abdominal Aortic Aneurysm Risk

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Y-Chromosome Loss and Its Association With Abdominal Aortic Aneurysm Risk
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationMen with genotyping and covariate data in the UK Biobank and Mass General Brigham Biobank; the study assessed associations between LOY and aortic aneurysm incidence.
Care SettingCare setting described in the source article.

Key Highlights

  • In the UK Biobank, adjusted AAA risk increased across mid- and high-cell-fraction LOY groups; the low-cell-fraction estimate was not statistically significant.
  • Continuous LOY burden was associated with AAA incidence in the UK Biobank (sHR 1.02 per 1% cell-fraction increase; 95% CI, 1.01-1.04).
  • The Mass General Brigham Biobank showed an association between high-cell-fraction LOY and AAA (aOR 1.38; 95% CI, 1.02-1.87); lower-category estimates were not statistically significant.
  • Neither cohort found a statistically significant association between LOY and TAA.

Guideline-Based Recommendations

Diagnosis

  • The study identified AAA and TAA using ICD-9, ICD-10, and procedure codes; Mass General Brigham Biobank diagnoses were additionally confirmed through radiology reports.

Management

    Monitoring & Follow-up

      Risks

      • In the UK Biobank, greater LOY burden was associated with higher AAA risk after adjustment for age, smoking, type 2 diabetes, hyperlipidemia, hypertension, and genetic principal components.
      • The observational study does not establish that LOY causes AAA.
      • Neither cohort found a statistically significant association between LOY and TAA.

      Patient & Prescribing Data

      The UK Biobank analysis included 221,486 men without known aortic aneurysms at baseline; the validation cohort included 14,569 men. The study did not evaluate a treatment or prescribing intervention.

      No treatment was studied. The article states that no effective treatment is currently available to prevent AAA enlargement.

      Clinical Best Practices

        Related Resources & Content

        Original Source(s)

        Related Content